Corline Biomedical AB (CLBIO) — Cash Flow Reinvestment Rate
Corline Biomedical AB (CLBIO) has a Cash Flow Reinvestment Rate of 1.60x as of March 2024, reinvesting Skr3.67 Million (capex Skr1.83 Million plus investments Skr-1.83 Million) from operating cash flow of Skr2.30 Million. See CLBIO free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Corline Biomedical AB Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Corline Biomedical AB across 1 annual periods. For the full cash flow conversion analysis, see Corline Biomedical AB (CLBIO) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Corline Biomedical AB (2023–2023)
Year-by-year capital reinvestment analysis for Corline Biomedical AB. See Corline Biomedical AB financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 23.23x | Skr20.59 Million | Skr886.00K | Skr10.62 Million | — |